Lawyers for Merck & Co. told the Supreme Court on Monday that investors waited too late and didn’t do all of the necessary investigations to sue the drugmaker over whether it properly warned about the risks of its blockbuster painkiller Vioxx.
Merck vows to press ahead with Vioxx defense
[LatelineNews 2005-09-09] NEW YORK - On the eve of a second court battle over its arthritis drug Vioxx, Merck & Co. Inc. said on Friday it does not plan to enter into any global settlement of the thousands of Vioxx lawsuits it faces and is focused on "defending these cases one at a time."
Merck tells regulators Vioxx replacement is safe
Readington-based Merck & Co.'s arthritis drug Arcoxia, successor to its withdrawn Vioxx, should be approved by U.S. regulators because it's easier on the stomach than pills already on the market and poses no greater risks to the heart, Merck said.
Merck pulled Vioxx off the market in September 2004 after the drug, which had annual sales of $2.5 billion, was shown to double the risk of heart attack and stroke among people taking it for 18 months or longer.
Contact:
Copyright © 2005 Vioxx Advisor.com All Rights Reserved